| Liu, Hong |
NCT06142552: Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein |
|
|
| Recruiting | 3 | 120 | RoW | FRSW117, Recombinant human coagulation factor Ⅷ-Fc fusion protein for injection | Jiangsu Gensciences lnc. | Severe Hemophilia A | 01/26 | 09/26 | | |
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 150 | RoW | SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) | Antengene Corporation | Relapsed or Refractory Multiple Myeloma | 07/24 | 10/24 | | |
NCT04836520: SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer. |
|
|
| Completed | 2 | 20 | RoW | SHR6390+anatrozole | Tianjin Medical University Cancer Institute and Hospital, Jiangsu HengRui Medicine Co., Ltd. | Breast Cancer | 02/23 | 03/23 | | |
NCT04562870 / 2020-003809-60: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis |
|
|
| Active, not recruiting | 2 | 112 | Europe, US, RoW | Selinexor, Physician's Choice Treatment | Karyopharm Therapeutics Inc | Myelofibrosis | 01/25 | 01/25 | | |
|
|
| Active, not recruiting | 1/2 | 121 | RoW | CAR-BCMA T Cells | CARsgen Therapeutics Co., Ltd., Beijing Chao Yang Hospital, The First Affiliated Hospital of Soochow University, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Tianjin Medical University General Hospital, First Affiliated Hospital of Zhejiang University, Beijing Hospital, Shanghai Tongji Hospital, Tongji University School of Medicine, First Affiliated Hospital of Wenzhou Medical University, Xiangya Hospital of Central South University, Peking University People's Hospital, Qilu Hospital of Shandong University, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University | Multiple Myeloma | 12/24 | 12/25 | | |
NCT05881655: Slow Myopia Progression With Different Irradiance Light |
|
|
| Recruiting | N/A | 75 | RoW | Airdoc Red Lighting Device, Repeated Red Light, Low Lever Laser Therapy, Low Intensity Light Therapy, Photobiomodulation Therapy, Seconee, 650nm Red Light, Special Spectacles to Control Myopia, Essilor® Stellest™ Lenses, H.A.L.T lens | Beijing Airdoc Technology Co., Ltd., Shanghai Children's Medical Center | Myopia, Progressive | 05/24 | 12/25 | | |
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma |
|
|
| Active, not recruiting | N/A | 1000 | RoW | No Intervention | Takeda | Lymphoma | 06/26 | 06/26 | | |
| Yang, Nong |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Recruiting | 2 | 200 | RoW | BEBT-109 Capsule, KCBT-1083 | BeBetter Med Inc | Non-Small Cell Lung Cancer, EGFR Exon 20 Insertion Mutation | 12/25 | 06/26 | | |
NCT05001971: Anlotinib Plus Penpulimab for the Treatment of Sensitive Relapsed Small-Cell Lung Cancer |
|
|
| Recruiting | 2 | 73 | RoW | Anlotinib Plus Penpulimab, Anlotinib & Penpulimab | Hunan Cancer Hospital, Fuzhou Pulmonary Hospital of Fujian, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Small Cell Lung Cancer | 06/23 | 12/23 | | |
NCT05411679: EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer |
|
|
| Withdrawn | 2 | 115 | RoW | EP0057, Olaparib tablets | Ellipses Pharma | Gastric Cancer, Small-cell Lung Cancer | 08/24 | 12/24 | | |
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 498 | Europe, RoW | SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate | Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 12/25 | 10/26 | | |
| Recruiting | 1/2 | 280 | RoW | SAF-189s, foritinib succinate | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell | 12/22 | 03/26 | | |
NCT05329298: A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 90 | RoW | BPI-361175 | Betta Pharmaceuticals Co., Ltd. | Non-small Cell Lung Cancer | 06/23 | 12/23 | | |
NCT04993391: AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 156 | RoW | JS111(AP-L1898 Capsules) | Suzhou Junjing BioSciences Co., Ltd. | Lung Cancer | 06/24 | 08/24 | | |
| Recruiting | 1/2 | 500 | Europe, Canada, Japan, US, RoW | Oral repotrectinib (TPX-0005), repotrectinib | Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd. | Locally Advanced Solid Tumors, Metastatic Solid Tumors | 02/28 | 02/28 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NCT04825392: A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 30 | RoW | HX008 | Taizhou Hanzhong biomedical co. LTD | Advanced Solid Tumor | 05/21 | 12/21 | | |
NCT04675060: Effect of High-fat Meal on the Pharmacokinetics of TQ-B3139 Capsules |
|
|
| Recruiting | 1 | 12 | RoW | TQ-B3139 capsules | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Solid Tumors | 03/22 | 03/22 | | |
NCT05337267: Phase I Study of Sintilimab in Healthy Chinese Male Subjects |
|
|
| Completed | 1 | 117 | RoW | sintilimab (after the change), sintilimab (before the change) | Innovent Biologics (Suzhou) Co. Ltd. | Healthy Male Subjects | 05/23 | 07/23 | | |
NCT05559242: Pharmacokinetic Study of Anlotinib Hydrochloride Capsules in Healthy Subjects and Liver Dysfunction Patients |
|
|
| Not yet recruiting | 1 | 30 | RoW | Anlotinib Hydrochloride Capsule | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Liver Dysfunction | 06/23 | 07/23 | | |
NCT05673538: TT-00973-MS Tablets in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 40 | RoW | TT-00973-MS tablets treatment | TransThera Sciences (Nanjing), Inc. | Advanced Solid Tumor | 12/24 | 12/25 | | |
| chen, xiang |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
NCT05181137 / 2021-001940-86: A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 3 | 368 | Europe, US, RoW | SHR0302, Placebo | Reistone Biopharma Company Limited, Reistone Biopharma Company Limited | Ulcerative Colitis | 10/24 | 03/25 | | |
NCT06365502: Preventive Drug-coated Balloon Angioplasty in Vulnerable Atherosclerotic Plaque (RESTORE Trial) |
|
|
| Recruiting | N/A | 1860 | RoW | Drug-coated balloon, Guideline-directed medical treatment | Harbin Medical University, Shanghai Shenqi Medical Technology Co., Ltd | Acute Coronary Syndrome (ACS) | 12/27 | 12/30 | | |
| Zhang, Yongchang |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
NCT06057571: Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor |
|
|
| Recruiting | 2 | 50 | RoW | TT-00420 (tinengotinib) | TransThera Sciences (Nanjing), Inc. | Cholangiocarcinoma Metastatic | 06/25 | 10/25 | | |
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 498 | Europe, RoW | SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate | Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 12/25 | 10/26 | | |
Helpful, NCT06521034: First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer |
|
|
| Completed | 1/2 | 124 | RoW | FHND-9041, EGFR-TKI | Yongchang Zhang, Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer, EGFR Gene Mutation, EGFR-TKI Sensitizing Mutation | 05/21 | 05/21 | | |
NCT06166472: A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor |
|
|
| Not yet recruiting | 1 | 72 | RoW | AK132 | Akeso | Advanced Malignant Solid Tumor | 04/26 | 07/26 | | |
| Recruiting | 1 | 117 | RoW | SG2918 | Hangzhou Sumgen Biotech Co., Ltd. | Advanced Malignant Tumors | 12/25 | 12/26 | | |
| Recruiting | 1 | 150 | RoW | TQB2922 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Advanced Cancer | 12/24 | 12/25 | | |
CIBI343A101, NCT05458219: A First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 470 | US, RoW | IBI343 | Innovent Biologics (Suzhou) Co. Ltd., Innovent Biologics, Inc., TigerMed | Locally Advanced Unresectable or Metastatic Solid Tumors | 12/25 | 12/25 | | |
| Recruiting | 1 | 556 | RoW | IBI363 + chemotherapy, IBI363 + Investigator's Choice SOC | Innovent Biologics (Suzhou) Co. Ltd. | Advanced Malignancies | 06/25 | 12/26 | | |
NCT06536400: Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation |
|
|
| Recruiting | 1 | 316 | RoW | HSK42360 | Haisco Pharmaceutical Group Co., Ltd. | Solid Tumors | 08/26 | 07/27 | | |
| Recruiting | 1 | 122 | RoW | SG1827 | Hangzhou Sumgen Biotech Co., Ltd. | Advanced Solid Tumors | 12/24 | 03/25 | | |
| Recruiting | 1 | 71 | RoW | TQB2103 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Advanced Malignant Neoplasm | 05/25 | 05/25 | | |
